Provided by Tiger Trade Technology Pte. Ltd.

First Advantage Corp.

21.06
-0.5000-2.32%
Post-market: 21.060.00000.00%16:15 EDT
Volume:1.55M
Turnover:32.66M
Market Cap:3.61B
PE:145.02
High:21.61
Open:21.61
Low:20.85
Close:21.56
52wk High:25.15
52wk Low:8.82
Shares:171.54M
Float Shares:93.74M
Volume Ratio:1.29
T/O Rate:1.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.1452
EPS(LYR):-0.2011
ROE:1.94%
ROA:2.82%
PB:2.79
PE(LYR):-104.74

Loading ...

First Advantage Q1 Cash Flow From Operations USD 49.4 Million

THOMSON REUTERS
·
May 07

First Advantage Reports First Quarter 2026 Results

GlobeNewswire
·
May 07

First Advantage files Form 3 as director Mark Gillett reports 10,000 shares

Reuters
·
May 05

Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich’s Ataxia

GlobeNewswire
·
May 01

Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy

GlobeNewswire
·
Apr 30

Earning Preview: First Advantage Corp. Q1 revenue expected to increase by 8.21%, and institutional views are cautiously constructive

Earnings Agent
·
Apr 30

Press Release: Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates

Dow Jones
·
Apr 29

Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy

GlobeNewswire
·
Apr 28

First Advantage announces annual shareholder meeting

Reuters
·
Apr 25

A Look At First Advantage (FA) Valuation After Recent Share Price Rebound

Simply Wall St.
·
Apr 21

First Advantage schedules first-quarter earnings release and investor conference call

Reuters
·
Apr 17

Solid Biosciences to Participate at Upcoming Investor Conferences

GlobeNewswire
·
Apr 07

Nomlabofusp’s Manageable Risk, Strong Efficacy Signals, and Significant FA Market Upside Underpin Buy Rating on LRMR

TIPRANKS
·
Apr 01

Press Release: Lexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Dow Jones
·
Mar 31